Anzeige
Meldung des Tages: China drosselt, Westen unter Druck: Entsteht hier der nächste Rohstoff-Explosionsmarkt?

Alkermes News

Aktie
WKN:  A1JKVH ISIN:  IE00B56GVS15 US-Symbol:  ALKS
30,00 €
-0,3 €
-0,99%
08:37:00 Uhr
Depot/Watchlist
Marktkapitalisierung *
3,94 Mrd. €
Streubesitz
100,00%
KGV
-
Index-Zuordnung
-

Alkermes News

11.11.24 - PR Newswire
Alkermes to Participate in Two Upcoming Investor Conferences
Alkermes to Participate in Two Upcoming Investor Conferences PR Newswire
11.11.24 - PR Newswire
Alkermes to Participate in Two Upcoming Investor Conferences
Alkermes to Participate in Two Upcoming Investor Conferences PR Newswire
07.11.24 - PR Newswire
Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences
Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences PR Newswire
07.11.24 - PR Newswire
Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences
Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences PR Newswire
24.10.24 - PR Newswire
Alkermes plc Reports Third Quarter 2024 Financial Results
Alkermes plc Reports Third Quarter 2024 Financial Results PR Newswire
24.10.24 - PR Newswire
Alkermes plc Reports Third Quarter 2024 Financial Results
Alkermes plc Reports Third Quarter 2024 Financial Results PR Newswire
17.10.24 - PR Newswire
Alkermes to Report Third Quarter Financial Results on October 24, 2024
Alkermes to Report Third Quarter Financial Results on October 24, 2024 PR Newswire
25.09.24 - PR Newswire
Alkermes to Host Investor Event to Review Orexin Portfolio Strategy
Alkermes to Host Investor Event to Review Orexin Portfolio Strategy PR Newswire
25.09.24 - PR Newswire
Alkermes to Host Investor Event to Review Orexin Portfolio Strategy
Alkermes to Host Investor Event to Review Orexin Portfolio Strategy PR Newswire
23.09.24 - PR Newswire
Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024
Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024 PR Newswire
23.09.24 - PR Newswire
Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024
Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024 PR Newswire
19.09.24 - PR Newswire
Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference
Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference PR Newswire
13.09.24 - PR Newswire
Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program
Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program PR Newswire
13.09.24 - PR Newswire
Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program
Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program PR Newswire
28.08.24 - PR Newswire
Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference PR Newswire
28.08.24 - PR Newswire
Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference PR Newswire
22.08.24 - PR Newswire
Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2
Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 PR Newswire
22.08.24 - PR Newswire
Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2
Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 PR Newswire
24.07.24 - Börse-Global
Alkermes Aktie: Solide Quartalsergebnisse trotz Umsatzrückgang
Alkermes plc, ein führendes biopharmazeutisches Unternehmen, hat seine Finanzergebnisse für das zweite Quartal 2024 veröffentlicht. Trotz eines Umsatzrückgangs von 35,4% ...
24.07.24 - PR Newswire
Alkermes plc Reports Second Quarter 2024 Financial Results
Alkermes plc Reports Second Quarter 2024 Financial Results PR Newswire

Newssuche

Videos

newspaper
01.04.26
Saisonalitäten: DAS machst Du falsch!
Viele Trader landen irgendwann bei Saisonalitäten, ziehen diesen stark fundamental basierten Ansatz ... Mehr »